Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study

Clinical trial NCT07486869 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07486869
Sponsor: University of Miami
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Dermatomyositis Dermatomyositis Sine Myositis Dermatomyositis With Myopathy Dermatomyositis With Respiratory Involvement Dermatomyositis With Organ Involvement Interstitial Lung Disease Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)

Start date: 2026-07-01
Primary completion: 2027-05-01
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.